More positive coverage
Impedimed has flagged potential new markets for its device, such as monitoring a build up of heart fluid.
"This is a much larger potential market, therefore 2016 could be transformational for Impedimed," Smith said, where he has a $1.90 price target.
http://www.theage.com.au/business/m...l-biotechs-20151228-glvrek.html#ixzz3wHBpEj77
